Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction.
Adolescent
ICS
LABA
asthma
fluticasone furoate
fluticasone propionate
formoterol
inhaled corticosteroid
long-acting β-agonist
lung function
vilanterol
Journal
The journal of allergy and clinical immunology. Global
ISSN: 2772-8293
Titre abrégé: J Allergy Clin Immunol Glob
Pays: United States
ID NLM: 9918453488706676
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
22
09
2023
revised:
09
02
2024
accepted:
15
02
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
epublish
Résumé
The combination of an inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) (ICS/LABA) has shown superiority in improving lung function (FEV We sought to compare the efficacy of 2 combinations of an ICS and LABA, namely, fluticasone propionate (FP) and formoterol (FORM) (FP/FORM) and fluticasone furoate (FF) and vilanterol (VI) (FF/VI), in asthmatic adolescents with chronic bronchial obstruction. FP/FORM (125 μg/5 μg, 2 doses twice daily via the k-haler [Mundipharma, Cambridge, UK]) and FF/VI (92 μg/22 μg, once daily via the Ellipta inhaler [GlaxoSmithKline]) were administered to adolescents aged 12 to 17 years who required regular antiasthmatic medication and had a ratio of FEV Both ICS/LABA combinations resulted in a significant improvement in FEV Both ICS/LABA combinations demonstrated significant improvements in FEV
Sections du résumé
Background
UNASSIGNED
The combination of an inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) (ICS/LABA) has shown superiority in improving lung function (FEV
Objective
UNASSIGNED
We sought to compare the efficacy of 2 combinations of an ICS and LABA, namely, fluticasone propionate (FP) and formoterol (FORM) (FP/FORM) and fluticasone furoate (FF) and vilanterol (VI) (FF/VI), in asthmatic adolescents with chronic bronchial obstruction.
Methods
UNASSIGNED
FP/FORM (125 μg/5 μg, 2 doses twice daily via the k-haler [Mundipharma, Cambridge, UK]) and FF/VI (92 μg/22 μg, once daily via the Ellipta inhaler [GlaxoSmithKline]) were administered to adolescents aged 12 to 17 years who required regular antiasthmatic medication and had a ratio of FEV
Results
UNASSIGNED
Both ICS/LABA combinations resulted in a significant improvement in FEV
Conclusion
UNASSIGNED
Both ICS/LABA combinations demonstrated significant improvements in FEV
Identifiants
pubmed: 38826625
doi: 10.1016/j.jacig.2024.100268
pii: S2772-8293(24)00064-X
pmc: PMC11141437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100268Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Supported by the Finnish Allergy Research Foundation, the Finnish Respiratory Disease Research Foundation, the Foundation for Paediatric Research, the Foundation of Finnish Anti-Tuberculosis Association, The Finnish Medical Foundation, Finland, the 10.13039/100007634Ida Montin Foundation, the 10.13039/501100006706Tampere Tuberculosis Foundation, and the Väinö and Laina Kivi Foundation. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.